News & Views | Published:

Stem cells

HSCT for Crohn's disease: work in progress or a bridge too far?

Nature Reviews Gastroenterology & Hepatology volume 13, pages 128130 (2016) | Download Citation

Haematopoietic stem cell transplantation for refractory Crohn's disease has the potential to halt therapy-resistant inflammation. Hawkey et al. argue that HSCT does not offer sustained benefit based upon their recent study; however, their study was designed using suboptimal end points and patients were not offered post-transplantation Crohn's disease medication.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Autologous hematopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA 314, 2524–2534 (2015).

  2. 2.

    , & Stem cells as potential novel therapeutic strategy for inflammatory bowel disease. J. Crohns Colitis 2, 99–106 (2008).

  3. 3.

    et al. Risks of immune system treatments. Science 328, 825–826 (2010).

  4. 4.

    et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J. Exp. Med. 201, 805–816 (2005).

  5. 5.

    et al. Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-β-producing CD8+ Treg cells are associated with immunological remission of lupus. J. Immunol. 183, 6346–6358 (2009).

  6. 6.

    et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up. Blood 116, 6123–6132 (2010).

  7. 7.

    et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371, 660–667 (2008).

  8. 8.

    et al. Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort. Gut 55, 510–518 (2006).

  9. 9.

    et al. Serious infections and mortality in associations with therapies for Crohn's disease: TREAT registry. Clin. Gastroent. Hepatol. 4, 621–630 (2006).

  10. 10.

    et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group For Blood And Marrow Transplantation Working Party On Autoimmune Diseases. Haematologica 95, 284–292 (2010).

Download references

Author information

Affiliations

  1. Daniel W. Hommes and Precious N. Lacey are at the UCLA Center for Inflammatory Bowel Diseases, Division of Digestive Diseases, 10945 Le Conte Avenue #2338E, Los Angeles, California 90095, USA.

    • Daniel W. Hommes
    •  & Precious N. Lacey

Authors

  1. Search for Daniel W. Hommes in:

  2. Search for Precious N. Lacey in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Daniel W. Hommes.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrgastro.2016.22

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing